Supratherapeutic INR resulting from the initiation of warfarin in a patient receiving axitinib

Abstract

Axitinib is a vascular endothelial growth factor receptor inhibitor indicated for advanced renal cell cancer after failure of one prior systemic therapy. We report a case where a patient receiving axitinib experienced a supratherapeutic INR soon after initiation of an age-appropriate warfarin dose. We propose two possible mechanisms for this interaction, including competitive protein binding and decreased metabolism. Close INR monitoring and dose adjustments of warfarin may be necessary in patients receiving concomitant axitinib and warfarin in order to decrease the risks associated with this interaction.

Keywords

Warfarin axitinib INR interaction

Get full access to this article

View all access options for this article.

References

National Comprehensive Cancer Network. Cancer-associated venous thromboembolic disease, http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf (2015, accessed 5 October 2015).

Lee

Levine

Bajer

et al.

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349: 146–153.

Inlyta® [package insert]. New York, NY: Pfizer Labs, Division of Pfizer, Inc, 2014.

Coumadin® [package insert]. Princeton, NJ: Bristol-Meyers Squibb, 2011.